Gambaran Ketahanan Hidup (Kesintasan) Satu Tahun Pasien Koinfeksi TB-HIV Berdasarkan Waktu Awal Pengobatan Antiretroval (ARV) pada Fase Lanjut di Rumah Sakit Penyakit Infeksi (RSPI) Prof. Dr. Sulianti Saroso Periode Januari 2011-Mei 2014
Downloads
Abstrak
Latar Belakang : Human Immunodeficiency Virus (HIV) merupakan jenis retrovirus yang menginfeksi sistem kekebalan tubuh manusia yang menyebabkan Acquired Immunodefiency Syndrome (AIDS),. Kehadiran kuman TB menyebabkan progresivitas kasus ko-infeksi TB-HIV bertambah buruk sehingga mengancam jiwa penderitanya. Penelitian ini bertujuan untuk mengetahui gambaran kesintasan satu tahun pasien ko-infeksi TB-HIV berdasarkan waktu awal pengobatan ARV.
Metode : Penelitian ini menggunakan desain kohort retrospektif di RSPI Prof. Dr. Sulianti Saroso tahun 2013-2015. Sumber data yang digunakan berasal dari penelusuran pada register pra ARV dan ARV, Form TB 01, buku monitoring ARV, monitoring farmasi ARV, pelacakan ikhtisar ARV dan status rekam medis. Pengumpulan data melibatkan petugas Pokja HIV/AIDS dan dokter (validasi diagnosa dan kovariat) yang di blind atas hipotesis penelitian.
Hasil : Probabilitas ketahanan hidup kumulatif satu tahun pasien ko-infeksi TB-HIV yang mendapatkan awal pengobatan ARV di RSPI Prof. Dr. Sulianti Saroso periode Januari 2011-Mei 2014 adalah 81,5%. Probabilitas ketahanan hidup pasien TB-HIV berdasarkan waktu awal menunjukan bahwa ketahanan hidup satu tahun pada pasien yang mendapatkan pengobatan ARV pada fase intensif adalah 89,1% dan pada pasien yang mendapatkan pengobatan ARV pada fase lanjut adalah 74,5%.
Kesimpulan : Pasien ko-infeksi TB-HIV yang mendapatkan ARV pada fase intensif cenderung memiliki probalitas ketahanan hidup yang lebih besar di tahun pertama dibandingkan pasien ko-infeksi TB-HIV yang mendapatkan ARV pada fase lanjut.
Â
Abstract Background : Human Immunodeficiency Virus (HIV) is a type of retrovirus that infects the human immune system that causes Acquired Immunodefiency Syndrome (AIDS). The presence of TB germs cause progression of cases of co-infection of TB-HIV getting worse so threatening sufferers. This study aims to reveal the one-year survival rate of patients co-infected TB-HIV based on time start of antiretroviral treatment.
Methods : This study used a retrospective cohort design in RSPI Prof. Dr. Sulianti Saroso years 2013-2015. The data used comes from searches on the register of pre ARV and ARV form, TB Form, the book ARV monitoring, monitoring of pharmaceutical drugs, ARV overview and status tracking of medical records. The data collection involves the officer HIV / AIDS and the doctor (validation diagnosis and covariates) were in blind on the research hypothesis. Results : The cumulative probability of survival for one year patients co-infected TB-HIV get antiretroviral treatment early in RSPI Prof. Dr. Sulianti Saroso period January 2011-May 2014 was 81.5%. The probability of survival for patients of TB-HIV based on the initial time showed that one-year survival in patients receiving antiretroviral treatment in the intensive phase was 89.1% and in patients receiving antiretroviral treatment in advanced phases was 74.5%.
Conclusion : Co-infected TB-HIV patients get antiretroviral drugs in the intensive phase tend to have a probability of survival is greater in the first year compared to co-infection TB-HIV patients get antiretroviral drugs in the advanced phase
Downloads
World Health Organization (WHO). Global Tuberculosis Report. 2014.
Kemenkes RI. Statistik Kasus HIV/AIDS di Indonesia Dilapor s/d September 2014. Jakarta; 2014.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2013;272.
Albrecht D, Altfeld M, Behrens G, Bredeek UF, Buhk T, Dickinson L, et al. HIV Medicine 2007 [Internet]. HIV Medicine. 2007. 818 p. Available from: www.HIVMedicine.com
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med [Internet]. 2010;362(8):697–706. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20181971&retmode=ref&cmd=prlinks%5Cnpapers2://publication/doi/10.1056/NEJMoa0905848
Cortes CP, Sterling TR, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, et al. Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. PLoS One. 2013;8(9):1–8.
Török ME, Thi N, Yen B, Thi T, Chau H, Thi N, et al. Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus ( HIV )– Associated Tuberculous Meningitis. Clin Infect Dis [Internet]. 2011;52(11):1374–83. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340579/pdf/emss-62280.pdf
Kiertiburanakul, S., Manosuthi, W., Sungkanuparph S. Optimal Timing Of Antiretroviral Therapy Initiation In Patients Coinfected With HIV And Tuberculosis. Expert Rev Clin Pharmacol. 2011;4:143–6.
Ismail I, Bulgiba A. Predictors of Death during Tuberculosis Treatment in TB/HIV Co-Infected Patients in Malaysia. PLoS One. 2013;8(8):1–7.
Anggraeni ND. Ketahanan Hidup Satu Tahun Pasien HIV/AIDS dengan Pengobatan Regimen ARV Lini Pertama Berdasarkan Jumlah CD4 Sebelum Pengobatan ARV di RSPI Prof. DR. Sulianti Saroso Tahun 2005-2010. Universitas Indonesia; 2010.
Melani. Pengaruh koinfeksi tuberkulosis terhadap kesintasan tiga tahun pasien HIV / AIDS yang mendapat terapi antiretroviral di Rumah Sakit penyakit infeksi Prof DR Sulianti Saroso tahun 2009-2011 = Impact of tuberculosis co infection on three year survival among. 2011;2011.
Havlir D V, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482–91.
